Ginkgo Bioworks Holdings, Inc. is an American biotechnology company specializing in cell engineering. Its ambition is to make it easier to design organisms capable of producing molecules or performing functions useful to industry. Based in Boston, it works with companies in pharmaceuticals, agriculture and materials, combining biology, software, robotics and data analysis.
A company born out of MIT
Ginkgo Bioworks was founded in 2008 by five scientists connected to the Massachusetts Institute of Technology: Jason Kelly, Reshma Shetty, Barry Canton, Austin Che and Tom Knight. The team advocates an engineering-inspired approach to biology: standardizing methods, automating experiments and reusing knowledge gained from one project in the next.
The company gradually developed its automated laboratories, known as “foundries,” before listing on the New York Stock Exchange in 2021 through a merger with a publicly listed acquisition vehicle, or SPAC. Its shares trade under the ticker symbol DNA. In 2022, the acquisition of Zymergen strengthened its technological capabilities. This expansion phase was followed by a restructuring announced in 2024, aimed in particular at cutting costs and streamlining infrastructure.
Designing, testing and measuring biological systems
Ginkgo’s historical core business is a cell programming platform. Starting from a goal defined with a client, its teams design genetic modifications, build different variants and measure their performance. These design and experimentation cycles can be used to improve an enzyme, optimize a microbial strain or explore avenues for therapeutic research.
Automation makes it possible to increase the number of tests and make certain operations more reproducible. The data generated then feeds into analyses and computational models. Artificial intelligence fits into this approach: helping to guide experiments and predict biological properties without replacing laboratory validation.
Ginkgo also offers more targeted research services and tools, particularly in automation and biological data. Its Concentric business operates in biosurveillance, with collection and analysis programs designed to monitor the circulation of pathogens. Depending on the contracts, revenue may combine service payments, development milestone payments and a share of the value created by clients’ projects.
What next?
The main challenge is to turn costly scientific infrastructure into an economically sustainable business. Offering more modular services should make it possible to meet specific needs without systematically requiring extensive development programs. The value of this approach will, however, depend on demand and Ginkgo’s ability to control its spending.
Success will also be measured by the transition from laboratory results to reliable industrial applications. Production costs, scaling up and regulatory constraints remain decisive factors. For biosurveillance, continuity of funding and data governance are additional areas requiring attention. Ginkgo will therefore need to demonstrate that its platform delivers tangible benefits to its clients, beyond its ability to generate experiments alone.